Novartis announces safety and efficacy benefit of Jakavi® in global clinical trial of over 1,000 patients with myelofibrosis
(Thomson Reuters ONE) -
Novartis International AG /
Novartis announces safety and efficacy benefit of Jakavi® in global clinical
trial of over 1,000 patients with myelofibrosis
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Data from ongoing trial reinforces the safety profile of Jakavi(®
)(ruxolitinib) as seen in previous Phase III studies[1]
* Patients on Jakavi experienced a reduction in spleen size that was
maintained over time and a clinically meaningful improvement in symptoms[1]
* Jakavi is the only JAK inhibitor approved in more than 70 countries for
patients with myelofibrosis, an uncommon blood cancer marked by debilitating
symptoms[2]
Basel, December 8, 2014 - Novartis today announced data from the largest
clinical trial of myelofibrosis patients treated with Jakavi(®) (ruxolitinib),
supporting the safety profile and efficacy benefit as measured in primary and
secondary endpoints respectively[1]. In an analysis of 1,144 patients treated
with Jakavi to date in this ongoing expanded access study, 69% of patients
achieved >50% reduction in spleen size from baseline and patients also
experienced a clinically meaningful improvement in myelofibrosis symptom score,
important treatment goals for patients with myelofibrosis[1],[3].
Findings from the study were presented at the 56th Annual Meeting of the
American Society of Hematology (ASH) in San Francisco, California.
"Results to date from the JUMP study reinforce the critical role that Jakavi
plays in the treatment of myelofibrosis, a life-threatening and debilitating
blood cancer with limited treatment options," said Haifa Kathrin Al-Ali, MD,
University Hospital of Leipzig, Leipzig, Germany. "These data provide insight
into the real world experience of more than 1,000 patients living with
myelofibrosis and further validate the safety and efficacy of Jakavi as an
important treatment for myelofibrosis."
Novartis research and development efforts, in collaboration with Incyte
Corporation, include early-phase and post-marketing studies in myelofibrosis and
other myeloproliferative neoplasms. More than 50 abstracts on ruxolitinib are
being presented at ASH, including three oral presentations exploring
combinations of ruxolitinib with various investigational compounds, evaluating
the possibility of simultaneously targeting multiple cancer pathways that may be
involved in the pathogenesis of myelofibrosis.
"Data presented at ASH demonstrate our ongoing commitment to the myelofibrosis
community and reinforce the role of Jakavi as the current standard of care for
these patients," said Alessandro Riva, MD, Global Head, Novartis Oncology
Development and Medical Affairs. "It's exciting to see the depth of research in
a rare blood cancer like myelofibrosis. Results from these studies help us to
better understand and address the needs of patients and physicians."
About the JUMP Study
The JUMP study is a Phase IIIb, expanded-access trial for countries with no
access to Jakavi outside of a clinical trial. The open-label, multicenter study
analyzed 1,144 enrolled myelofibrosis patients who received daily starting doses
of either 5 mg, 15 mg or 20 mg of Jakavi twice daily based on platelet counts at
baseline. The primary endpoint is assessment of safety and tolerability of
Jakavi. Additional analyses included changes in spleen size and symptom scores
as measured by the FACT-Lymphoma Total Score (FACT-Lym TS). As of September
22, 2014, 2,138 patients were enrolled at more than 200 study sites in 25
countries, and the final analysis will be performed after all patients have
completed 24 months of treatment or ended treatment due to commercial
availability[1].
Overall, the safety and efficacy profile of Jakavi was consistent with previous
studies[1],[4],[5]. The most common Grade 3 or 4 hematologic adverse events
(AEs) were anemia (33.0%) and thrombocytopenia (12.5%); however, they rarely led
to discontinuation (2.6% of discontinuation was due to anemia and 3.2% of
discontinuation was due to thrombocytopenia)[1]. The most common nonhematologic
AEs were diarrhea (14.5%), fever (13.3%), fatigue (12.9%) and asthenia (12.5%),
which were primarily Grade 1 or 2[1].
Also at ASH: MPN Landmark Patient and Physician Survey
Also separately presented for the first time are results from the new MPN
Landmark Survey of physicians and patients with myeloproliferative neoplasms
(MPNs), a group of related blood cancers, including myelofibrosis[6],[7]. The
survey, conducted by Incyte Corporation, concluded that an essential goal in
disease management should focus on reducing symptom burden and improving quality
of life in order to enhance the overall health of patients with
myelofibrosis[6],[7].
The Landmark Survey found that a remarkable 81% of patients with myelofibrosis
reported their myelofibrosis-related symptoms reduced their quality of life[7].
The vast majority of myelofibrosis patients (81%) reported that fatigue was the
most severe and common symptom they experienced[7]. According to physicians
surveyed, fatigue, abdominal discomfort and pain had the greatest impact on
quality of life in their myelofibrosis patients[7]. In fact, both patients and
physicians agreed that fatigue is the most urgent symptom myelofibrosis patients
would like to resolve[6].
The MPN Landmark Survey is the first large US-based survey to examine both
physicians who treat MPNs and patients diagnosed with one of the three MPNs,
including myelofibrosis, polycythemia vera (PV) and essential thrombocythemia
(ET). The survey was completed by 457 physicians and 813 patients (MF=207;
PV=380; ET=226) who filled out an online survey of 59 to 65 questions (depending
on the MPN), conducted between May and July 2014. Participants were asked about
the overall burden of disease and impact of symptoms on quality of life,
productivity, and activities of daily living (ADLs). Symptom severity was
determined using the MPN Symptom Assessment Form total symptom scores (MPN-SAF
TSS), and descriptive analyses were conducted to identify gaps in perceptions of
disease burden and patient-physician communication[6],[7].
About Myelofibrosis
Myelofibrosis is a rare, life-threatening blood cancer, with approximately 1 in
every 133,000 people estimated to be affected by the disease[2],[8],[9].
Myelofibrosis develops when uncontrolled signaling in the JAK pathway - which
regulates blood cell production - causes the body to make blood cells that do
not work properly, which scars the bone marrow and results in an enlarged spleen
as well as other severe complications and debilitating symptoms[2],[10].
Studies show that patients with myelofibrosis have a decreased life expectancy,
with a median overall survival of 5.7 years[11]. Although allogeneic stem cell
transplantation may cure myelofibrosis, the procedure is associated with
significant morbidity and transplant-related mortality and is available to less
than 5% of patients who are young and fit enough to undergo the procedure[12].
Current myelofibrosis treatment strategies are aimed at reducing spleen size,
relieving symptoms, improving quality of life and reducing the risk of
complications[3],[10].
About Jakavi
Jakavi (ruxolitinib) is an oral inhibitor of the JAK 1 and JAK 2 tyrosine
kinases and was approved by the European Commission in August 2012 for the
treatment of disease-related splenomegaly or symptoms in adult patients with
primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-
polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.
Jakavi is approved in more than 70 countries, including the European Union,
Canada, Japan and some countries in Asia, Latin and South America. Additional
worldwide regulatory filings are underway.
Novartis licensed ruxolitinib from Incyte Corporation for development and
commercialization outside the United States. Both the European Commission and
the U.S. Food and Drug Administration (FDA) granted ruxolitinib orphan drug
designation for myelofibrosis. Jakavi is marketed in the United States by Incyte
Corporation under the name Jakafi(®) for the treatment of patients with
intermediate or high-risk myelofibrosis.
The recommended starting dose for Jakavi in patients with myelofibrosis is 15 mg
twice daily for patients with a platelet count between 100,000 cubic millimeters
(mm(3)) and 200,000 mm(3), and 20 mg twice daily for patients with a platelet
count of >200,000 mm(3). Doses may be titrated based on safety and efficacy.
There is limited information to recommend a starting dose for patients with
platelet counts between 50,000/mm(3) and <100,000/mm(3). The maximum recommended
starting dose in these patients is 5 mg twice daily, and patients should be
titrated cautiously[13].
Jakavi is a registered trademark of Novartis AG in countries outside the United
States. Jakafi is a registered trademark of Incyte Corporation. The safety and
efficacy profile of Jakavi has not yet been established outside the approved
indication.
Jakavi(®) Important Safety Information
Jakavi can cause serious side effects, including a decrease in blood cell count
and infections. Complete blood count monitoring is recommended. Dose reduction
or interruption may be required in patients with any hepatic impairment or
severe renal impairment or in patients developing hematologic adverse reactions
such as thrombocytopenia, anemia and neutropenia. Dose reductions are also
recommended when Jakavi is co-administered with strong CYP3A4 inhibitors or
fluconazole. Use of Jakavi during pregnancy is not recommended, and women should
avoid becoming pregnant during Jakavi therapy. Women taking Jakavi should not
breast feed. The most common adverse drug reactions, occurring at any level of
severity (incidence >10%) are urinary tract infections, anemia,
thrombocytopenia, neutropenia, hypercholesterolemia, dizziness, headache,
alanine aminotransaminase increased, asparte aminotransferase increased and
bruising. Other common adverse drug reactions (incidence 1 to 10%) are herpes
zoster, weight gain, flatulence and tuberculosis (1%). Progressive multifocal
leukencephalopathy (PML) has been reported. Physicians should be alert for
neuropsychiatric symptoms suggestive of PML[13]. Please see full Prescribing
Information available at www.jakavi.com.
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by words such as "commitment," "will," "goal," "should," or similar terms, or by
express or implied discussions regarding potential new indications or labeling
for Jakavi, or regarding potential future revenues from Jakavi. You should not
place undue reliance on these statements. Such forward-looking statements are
based on the current beliefs and expectations of management regarding future
events, and are subject to significant known and unknown risks and
uncertainties. Should one or more of these risks or uncertainties materialize,
or should underlying assumptions prove incorrect, actual results may vary
materially from those set forth in the forward-looking statements. There can be
no guarantee that Jakavi will be submitted or approved for any additional
indications or labeling in any market, or at any particular time. Nor can there
be any guarantee that Jakavi will be commercially successful in the future. In
particular, management's expectations regarding Jakavi could be affected by,
among other things, the uncertainties inherent in research and development,
including unexpected clinical trial results and additional analysis of existing
clinical data; unexpected regulatory actions or delays or government regulation
generally; the company's ability to obtain or maintain proprietary intellectual
property protection; general economic and industry conditions; global trends
toward health care cost containment, including ongoing pricing pressures;
unexpected manufacturing issues, and other risks and factors referred to in
Novartis AG's current Form 20-F on file with the US Securities and Exchange
Commission. Novartis is providing the information in this press release as of
this date and does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care, cost-saving generic pharmaceuticals, preventive vaccines, over-the-
counter and animal health products. Novartis is the only global company with
leading positions in these areas. In 2013, the Group achieved net sales of USD
57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9
billion (USD 9.6 billion excluding impairment and amortization charges).
Novartis Group companies employ approximately 133,000 full-time-equivalent
associates and sell products in more than 150 countries around the world. For
more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
References
[1] Martino B, Coutre P, Griesshammer, et al. Safety and Efficacy of Ruxolitinib
in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients
with Myelofibrosis (MF): An 1144-Patient Update. Abstract #3197. 2014 American
Society of Hematology (ASH) Annual Meeting, San Francisco, CA.
[2] Leukemia & Lymphoma Society. "Myelofibrosis Facts." Available at:
http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials
/mpd/pdf/idiopathicmyelofibrosis.pdf. Accessed November 2014.
[3] Mesa RA. How I Treat Symptomatic Splenomegaly in Patients with
Myelofibrosis. Blood. 2009;113(22):5394-5400.
[4] Vannucchi, A, et al. Long-Term Outcomes From a Phase 3 Study Comparing
Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis
(MF): A 3 Year Update of Comfort II. Abstract #S1111.18(th) Congress of European
Hematology Association (EHA), 2013. Stockholm, Sweden.
[5] Verstovsek S, Ruben M, Gotlib J, et al. Long-Term Outcome of Ruxolitinib
Therapy in Patients with Myelofibrosis: 3-Year Update From COMFORT-I. Abstract
#396. 55th American Society of Hematology (ASH) Annual Meeting and Exposition,
2013. New Orleans, LA.
[6] Mesa R, Miller C, Thyne M, et al. Gaps in Perception Between Patients and
Physicians Regarding Symptomatology and Treatment Attitudes for
Myeloproliferative Neoplasms: MPN LANDMARK SURVEY. Abstract #4827. 2014 American
Society of Hematology (ASH) Annual Meeting, San Francisco, CA.
[7] Mesa R, Miller C, Thyne M, et al. Impact of Myeloproliferative Neoplasms
(MPNs) on Patients' Overall Health and Productivity: Results from the MPN
LANDMARK SURVEY in the United States. Abstract #3183. 2014 American Society of
Hematology (ASH) Annual Meeting, San Francisco, CA.
[8] Girodon F, Bonicelli G, Schaeffer C, et al. Significant Increase in the
Apparent Incidence of Essential Thrombocythemia Related to New Who Diagnostic
Criteria: A Population-Based Study. Haematologica. 2009; 94(6):865-869.
[9] McNally RJQ, Rowland D, Roman E, Cartwright RA. Age and Sex Distributions of
Hematological Malignancies in the U.K. Hematol Oncol. 1997;15:173-189.
[10] Mesa RA, Schwagera S, Radia D, et al. The Myelofibrosis Symptom Assessment
Form (MFSAF): An Evidence-Based Brief Inventory to Measure Quality of Life and
Symptomatic Response to Treatment in Myelofibrosis. Leuk Res. 2009;33:1199-1203.
[11] Cervantes F, Dupriez B, Pereira A, et al. New Prognostic Scoring System for
Primary Myelofibrosis based on a Study of the International Working Group for
Myelofibrosis Research and Treatment. Blood. 2009;113:2895-2901.
[12] Patriarca F, Bacigalupo A, Sperotto A, et al. Allogeneic Hematopoietic Stem
Cell Transplantation in Myelofibrosis: The 20-year Experience of the Gruppo
Italiano Trapianto di Midollo Osseo (GITMO). Haematologica.
2008;93(10):1514-1522.
[13] Jakavi(®) (ruxolitinib) tablets: EU Summary of Product Characteristics.
Novartis; Oct 2014.
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
Eric Althoff Maureen Byrne
Novartis Global Media Relations Novartis Oncology
+41 61 324 7999 (direct) +1 862 778 1518 (direct)
+41 79 593 4202 (mobile) +1 973 714 0063 (mobile)
eric.althoff(at)novartis.com maureen.byrne(at)novartis.com
e-mail: media.relations(at)novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis.
For questions about the site or required registration, please contact:
journalisthelp(at)thenewsmarket.com.
Novartis Investor Relations
Central phone: +41 61 324 7944
Samir Shah +41 61 324 7944 North America:
Pierre-Michel Bringer +41 61 324 1065 Stephen Rubino +1 862 778 8301
Thomas Hungerbuehler +41 61 324 8425 Susan Donofrio +1 862 778 9257
Isabella Zinck +41 61 324 7188
e-mail: investor.relations(at)novartis.com e-mail:
investor.relations(at)novartis.com
Media release (PDF):
http://hugin.info/134323/R/1878291/662069.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
[HUG#1878291]
Unternehmensinformation / Kurzprofil:
Datum: 08.12.2014 - 19:01 Uhr
Sprache: Deutsch
News-ID 357918
Anzahl Zeichen: 20364
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 197 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis announces safety and efficacy benefit of Jakavi® in global clinical trial of over 1,000 patients with myelofibrosis"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
